TECENTRIQ®
atezolizumab INJECTION FOR INTRAVENOUS USE 1200 mg

For previously treated metastatic non-small cell lung cancer

On behalf of Genentech, you are invited to attend an expert-led educational presentation

TECENTRIQ® for Previously Treated Metastatic Non-Small Cell Lung Cancer

Thursday, July 05, 2018
Arrival Time: 6:00 PM
Presentation Time: 6:45 PM

LB Steak
334 Santana Row
San Jose, CA 95128

FEATURED FACULTY
Ani Balmanoukian, MD
The Angeles Clinic and Research Institute
Los Angeles, CA

Please RSVP by Thursday, June 28, 2018 to:
Katrina Custodio at 650 273 3180
& custodio.katrina@gene.com
or at
https://www.geniersvp.com/SGEN9850?attendee=729135

PROGRAM OBJECTIVES:

- Present pivotal data from the OAK Phase 3 clinical trial
- Identify appropriate patient candidates with NSCLC for TECENTRIQ
- Review Important Safety Information
  - Describe warnings and precautions and additional information
- Provide PI recommendations for managing immune-mediated adverse reactions

INDICATION AND USAGE

TECENTRIQ® (atezolizumab) is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving TECENTRIQ.

Minnesota, New Jersey, Vermont, and Federal Entities (e.g., the Department of Defense and the Department of Veterans Affairs) have restrictions on receiving in-kind benefits (e.g., meals, valet parking) at company-sponsored events. You are accountable for understanding such restrictions and complying with them. If you are licensed in or affiliated with any of these states or federal agencies, Genentech policies may restrict you from consuming any portion of the Genentech-sponsored meal at this program or from receiving any other in-kind benefit from Genentech (e.g., valet parking) in connection with the program.

When you RSVP please indicate whether you will accept or opt out of Genentech's in-kind benefits (e.g., meals, valet parking) at the program. If you choose to opt out you may either pay for the meal and parking on your own, or not consume anything at the program.

For all program attendees who receive Genentech's in-kind benefits at this program, Genentech will report the attendee's name and the value received as required by federal and state disclosure laws (for more information on the federal law please visit sunshine.gene.com).

The meal cost may vary by event location and be up to $150 per person (exceptions may apply).

Please see accompanying full Prescribing Information and reverse for Important Safety Information.

Genentech
A Member of the Roche Group

IMPORTANT SAFETY INFORMATION

Serious Adverse Reactions

Please refer to the full Prescribing Information for important dose modification information specific to adverse reactions.

- **Immune-mediated pneumonitis.** Immune-mediated pneumonitis or interstitial lung disease, including fatal cases, have occurred. Permanently discontinue TECENTRIQ for Grade 3 or 4 pneumonitis
- **Immune-mediated hepatitis.** Immune-mediated hepatitis and liver test abnormalities, including fatal cases, have occurred. Permanently discontinue TECENTRIQ for AST or ALT elevations more than 8 times the upper limit of normal or total bilirubin more than 3 times the upper limit of normal
- **Immune-mediated colitis.** Immune-mediated colitis or diarrhea have occurred. Permanently discontinue TECENTRIQ for Grade 4 diarrhea or colitis
- **Immune-mediated endocrinopathies.** Thyroid disorders, adrenal insufficiency, type 1 diabetes mellitus, including diabetic ketoacidosis, and hypophysitis/hypopituitarism have occurred
- **Other immune-mediated adverse reactions.** TECENTRIQ can cause severe and fatal immune-mediated adverse reactions. These immune-mediated reactions may involve any organ system. Permanently discontinue TECENTRIQ for Grade 4 immune-mediated adverse reactions involving a major organ
- **Infections.** Severe infections, including fatal cases, have occurred
- **Infusion-related reactions.** Severe or life-threatening infusion-related reactions have occurred. Permanently discontinue TECENTRIQ in patients with Grade 3 or 4 infusion-related reactions
- **Embryo-fetal toxicity.** TECENTRIQ can cause fetal harm in pregnant women. Verify pregnancy status prior to initiating TECENTRIQ. Advise patients of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TECENTRIQ and for at least 5 months after the last dose
- Advise female patients not to breastfeed while taking TECENTRIQ and for at least 5 months after the last dose

Most Common Adverse Reactions

The most common adverse reactions in NSCLC (rate ≥20%) were fatigue (43.5%), decreased appetite (23.5%), dyspnea (22%), and cough (26.4%).

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see accompanying full Prescribing Information for additional Important Safety Information.

This event is sponsored by Genentech, Inc. No continuing education credits are offered with this program.

This presentation is intended for US healthcare providers only.

Genentech
A Member of the Roche Group

TECENTRIQ®
atezolizumab INJECTION FOR INTRAVENOUS USE 1200 mg